

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://FDILab.SciCrunch.org) on May 4, 2025

Mouse Anti-MEK1 / MEK2 Monoclonal Antibody, Unconjugated, Clone L38C12

RRID:AB_10695868

Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 4694, RRID:AB_10695868)

Antibody Information

URL: http://antibodyregistry.org/AB_10695868

Proper Citation: (Cell Signaling Technology Cat# 4694, RRID:AB_10695868)

Target Antigen: MEK1 / MEK2

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: W, IHC-P, IF-IC, F. Consolidation on 10/2018: AB_10695868, AB_390778.

Antibody Name: Mouse Anti-MEK1 / MEK2 Monoclonal Antibody, Unconjugated, Clone L38C12

Description: This monoclonal targets MEK1 / MEK2

Target Organism: monkey, rat, simian, mouse, human

Clone ID: Clone L38C12

Antibody ID: AB_10695868

Vendor: Cell Signaling Technology

Catalog Number: 4694

Record Creation Time: 20231110T044639+0000

Record Last Update: 20241115T040220+0000

Ratings and Alerts

No rating or validation information has been found for Mouse Anti-MEK1 / MEK2 Monoclonal Antibody, Unconjugated, Clone L38C12.

No alerts have been found for Mouse Anti-MEK1 / MEK2 Monoclonal Antibody, Unconjugated, Clone L38C12.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 41 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Yang SH, et al. (2024) Activated dormant stem cells recover spermatogenesis in chemoradiotherapy-induced infertility. Cell reports, 43(8), 114582.

Hicks HM, et al. (2024) The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies. Cancer biology & therapy, 25(1), 2332000.

Klomp JA, et al. (2024) Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers. Science (New York, N.Y.), 384(6700), eadk0775.

Kulkarni A, et al. (2024) Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcription. EMBO reports, 25(9), 3944.

Kim S, et al. (2023) Kinetics of RTK activation determine ERK reactivation and resistance to dual BRAF/MEK inhibition in melanoma. Cell reports, 42(6), 112570.

Randic T, et al. (2023) Single-cell transcriptomics of NRAS-mutated melanoma transitioning to drug resistance reveals P2RX7 as an indicator of early drug response. Cell reports, 42(7), 112696.

Xia Y, et al. (2023) Repositioning of Montelukast to inhibit proliferation of mutated KRAS pancreatic cancer through a novel mechanism that interfere the binding between KRAS and GTP/GDP. European journal of pharmacology, 961, 176157.

Müller L, et al. (2023) Plakophilin 3 facilitates G1/S phase transition and enhances

proliferation by capturing RB protein in the cytoplasm and promoting EGFR signaling. *Cell reports*, 42(1), 112031.

Shui B, et al. (2023) Oncogenic K-Ras suppresses global miRNA function. *Molecular cell*, 83(14), 2509.

Song Z, et al. (2023) Targeting of Annexin A1 in Tumor-associated Macrophages as a therapeutic strategy for hepatocellular carcinoma. *Biochemical pharmacology*, 213, 115612.

Ezzeldin S, et al. (2023) Detection of early prognostic biomarkers for metastasis of Ewing's sarcoma in pediatric patients. *Life sciences*, 334, 122237.

Fan Y, et al. (2023) Targeting LYPLAL1-mediated cGAS depalmitoylation enhances the response to anti-tumor immunotherapy. *Molecular cell*, 83(19), 3520.

Schaefer A, et al. (2023) RHOAL57V drives the development of diffuse gastric cancer through IGF1R-PAK1-YAP1 signaling. *Science signaling*, 16(816), eadg5289.

Wang Y, et al. (2023) Repositioning Lomitapide to block ZDHHC5-dependant palmitoylation on SSTR5 leads to anti-proliferation effect in preclinical pancreatic cancer models. *Cell death discovery*, 9(1), 60.

de Miguel FJ, et al. (2023) Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer. *Cancer cell*, 41(8), 1516.

Peterson AF, et al. (2022) Systematic analysis of the MAPK signaling network reveals MAP3K-driven control of cell fate. *Cell systems*, 13(11), 885.

Wu Q, et al. (2022) EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma. *Cancer discovery*, 12(5), 1378.

Grinat J, et al. (2022) Epigenetic modifier balances Mapk and Wnt signalling in differentiation of goblet and Paneth cells. *Life science alliance*, 5(4).

Wang W, et al. (2022) Sensing plasma membrane pore formation induces chemokine production in survivors of regulated necrosis. *Developmental cell*, 57(2), 228.

Zhao X, et al. (2022) Huntingtin exon 1 deletion does not alter the subcellular distribution of huntingtin and gene transcription in mice. *Frontiers in cellular neuroscience*, 16, 1021592.